Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Show More...

  • Website https://www.minervaneurosciences.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.54 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.09 -0.18 -4.47 -1.16 -0.99 -0.83 -1.29 -1.85 -1.75
    Dividends USD
    Payout Ratio % *
    Shares Mil 18.0 18.0 13.0 23.0 32.0 38.0 39.0 39.0 39.0
    Book Value Per Share * USD 3.08 2.55 3.23 3.36 2.6 1.42 0.47
    Free Cash Flow Per Share * USD -1.75 -1.04 -0.81 0.08 -1.06 -1.0
    Return on Assets % -755.8 -22.2 -116.57 -35.86 -28.81 -19.91 -31.08 -66.64 -68.99
    Financial Leverage (Average) 11.01 1.45 1.33 1.49 1.25 1.4 1.54 2.79 3.69
    Return on Equity % -32.3 -158.77 -50.71 -38.49 -26.54 -45.23 -122.3 -142.65
    Return on Invested Capital % -31.54 -153.05 -41.09 -33.36 -25.2 -45.13 -121.71 -141.7
    Interest Coverage -53.72 -26.76 -24.72 -29.15 -65.58 -453.25
    Current Ratio 1.1 1.29 5.51 6.29 8.66 18.94 24.94 7.11 5.4
    Quick Ratio 1.05 1.29 5.28 6.05 8.57 18.74 24.38 6.92 5.27
    Debt/Equity 0.15 0.04